HighCape Capital Acquisition II in an amended S-1 filing withdrew its planned offering of 20 million units. The SPAC initially registered the offering with the SEC in March 2021.
HighCape had planned to focus on companies engaged in life sciences and life sciences related industries.
The SPAC is led by CEO and Director Kevin Rakin, co-founder and partner of HighCape. He has more than 30 years of experience as an executive and investor in the life sciences industry, according to the initial filing.
The SPAC had planned to list on the Nasdaq. Read more.
